此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study (NAPOLI)

2026年8月30日 更新者:Ferrucci Massimo、Istituto Oncologico Veneto IRCCS

NAPOLI: Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study

The NAPOLI Study is a retrospective multicenter observational study designed to characterize hormone receptor-negative/low invasive lobular carcinoma of the breast. The study will collect real-world clinicopathological, molecular, therapeutic and outcome data from patients diagnosed and treated at participating centers. The aim is to describe the clinical behavior, pathological features, receptor profile, treatments received and oncologic outcomes of this rare breast cancer subtype.

研究概览

地位

招聘中

条件

干预/治疗

详细说明

Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer (BC), accounting for approximately 10-15% of all invasive BCs. ILC is characterized by loss or dysfunction of the E-cadherin/catenin adhesion complex, typically due to CDH1 alterations, and by a distinctive discohesive and infiltrative growth pattern. These features translate into specific and unique biological, clinical and therapeutic challenges compared with invasive carcinoma of no-special type (IC-NST).

The majority of ILCs - up to 90% - are estrogen receptor (ER)-positive, progesterone receptor (PR)-positive and HER2-negative. In contrast, hormone receptor (HR)-negative ILC (ER and PR expression <1%), HR-low ILC (1-10% HR-positive cells), and HER2-positive (any HR expression) ILC are rare, biologically and clinically heterogeneous, and markedly underrepresented in clinical trials and large translational datasets. Moreover, the absence or very low expression of hormone receptors limits the role of endocrine therapy, thereby narrowing therapeutic options and potentially affecting prognosis. The efficacy of anti-HER2 therapies in ILC remains less defined than in IC-NST, due to the rarity of HER2 overexpression in breast cancer of lobular histotype (<10% of all ILC). Consequently, clinical outcomes and response to neoadjuvant therapies across both HR-positive/HER2-positive and HR-negative/HER2-positive represent an area where clinical data are lacking.

Recent genomic and transcriptomic studies have identified alterations involving pathways such as CDH1, ERBB2, TP53, PI3K/AKT/PTEN, and DNA damage response pathways, along with other potentially actionable molecular mechanisms. These findings suggest that HR-negative/low ILC may constitute a biologically distinct entity rather than simply an uncommon variant of conventional HR-positive lobular carcinoma, raising important questions regarding prognosis, optimal treatment sequencing, indications and response to neoadjuvant therapies, and the potential role of targeted and biomarker-driven treatments.

Triple-negative ILC (TN-ILC) is exceedingly rare, accounting for approximately 1-2% of all ILC and well below 1% of all invasive BCs, which largely explains their marked underrepresentation in prospective trials, and the consequent lack of disease-specific evidence to guide clinical management. Available evidence suggests that TN-ILC is not simply the lobular counterpart of conventional basal-like triple-negative BC. Indeed, when profiled by PAM50, the majority of TN-ILC are non-basal-like, in contrast to conventional TN IC-NST. Moreover, TN-ILC appears enriched for older age at diagnosis, pleomorphic and apocrine/histiocytoid morphology, androgen receptor (AR) expression, and luminal androgen receptor (LAR)-like biology. Importantly, TN-ILC has been reported to show poor responsiveness to conventional neoadjuvant chemotherapy despite aggressive clinical behavior, raising questions about the optimal systemic treatment strategy and the potential value of biomarker-driven approaches. The few dedicated series available consistently report an unfavorable course, with a pooled pathologic complete response (PCR) rate of approximately 22.5%: in the largest early-stage cohort described to date, 5- and 10-year invasive disease-free survival were only approximately 50% and 37%, respectively. In addition, potentially actionable ERBB2 mutations have been reported in up to ~20% of TN-ILC and, together with frequent enrichment in DNA-damage-response, recurrent ESRRA mutations and PI3K/AKT/PTEN pathway alterations, may represent tractable therapeutic vulnerabilities, including HER2 tyrosine-kinase inhibitors, PARP or PI3K/AKT inhibitors.

HER2-positive ILC represents another uncommon and clinically relevant subgroup. HER2 overexpression/amplification in ILC is more frequently observed in pleomorphic and high-grade variants, and may be associated with distinct clinicopathologic features, higher proliferative activity and worse prognosis than classic HR-positive/HER2-negative ILC. However, data specific to HER2-positive ILC remain sparse, and most recommendations are extrapolated from IC-NST cohorts. Whether patterns of response to anti-HER2 neoadjuvant therapy, rates of PCR, surgical outcomes and recurrence patterns differ from those observed in IC-NST remains insufficiently defined.

Apocrine differentiation in the lobular setting is of particular interest, as it represents a rare and potentially distinct phenotype, commonly associated with HR negativity, AR expression, HER2 pathway activation in a subset of cases, luminal androgen receptor (LAR) biology, and unique genomic alterations, thereby providing a biological rationale for AR-directed or other targeted therapeutic strategies. In the lobular setting, apocrine, pleomorphic and histiocytoid features may overlap morphologically and biologically. However, the true prevalence, genomic correlates, treatment patterns and outcomes of apocrine lobular tumors remain poorly characterized. In the ductal setting TN apocrine carcinomas have shown markedly low PCR rates to neoadjuvant chemotherapy (as low as ~7%, versus ~30% in non-apocrine TN BC), and LAR-subtype tumors achieve the lowest PCR across TN subtypes (~14% versus ~43%). As apocrine and LAR features are enriched in HR-negative/low ILC, comparably low chemosensitivity is expected in this setting, further supporting a dedicated, biomarker-driven therapeutic approach.

Because of the rarity of these subtypes, prospective randomized studies are unlikely to be carried out in the near future. A large international real-world cohort is therefore needed to clarify whether HR-negative/low ILC, apocrine/LAR-enriched lobular tumors and HER2-positive ILC represent clinically meaningful and biologically distinct entities, and to identify potential prognostic and predictive biomarkers.

The NAPOLI study is designed to assemble a large international cohort of patients with HR-negative/low and/or HER2-positive ILC, with a special focus on apocrine/LAR features, molecular alterations, imaging presentation, multidisciplinary treatment patterns, response to neoadjuvant therapies, surgical and axillary management, recurrence patterns, and oncologic outcomes. The overarching aim is to generate disease-specific evidence to improve risk stratification, identify clinically relevant prognostic and predictive biomarkers, guide multidisciplinary management (i.e. the use of neoadjuvant chemotherapy) and support future translational and biomarker-driven studies in this rare and underexplored subgroup of BC.

研究类型

观察性的

注册 (估计的)

250

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不适用

取样方法

非概率样本

研究人群

Patients diagnosed between January 1, 2010 and December 31, 2025 will be included. Follow-up will be collected until the most recent available clinical update.

描述

Inclusion Criteria:

  • Female or male patients aged ≥18 years;
  • Histologically confirmed ILC, confirmed by E-cadherin loss/aberrant expression and/or p120 cytoplasmic relocalization and/or CDH1 alteration;
  • HR-negative (ER <1% and PR <1%) or HR-low (ER and/or PR 1-10%) disease, as defined by ASCO/CAP guidelines, is eligible regardless of HER2 status (assessed according to 2025 ASCO/CAP criteria, with HER2-low and HER2-ultralow status recorded where assessable);
  • HR-positive (ER>10% according to the ASCO/CAP guidelines) ILC is eligible only if HER2 status is positive;
  • Mixed ductal-lobular carcinomas are eligible provided that a clearly identified invasive lobular component is present and predominant (>50% lobular) and HR-negative/low criteria are met;
  • Stage I-III disease at diagnosis; Patients with de novo stage IV disease who underwent surgery of the primary tumor will not be included in the main study cohort but may be captured in a separate exploratory cohort for dedicated analysis;
  • Patients who underwent surgery of the primary tumor at the participating institution, either upfront or after neoadjuvant systemic treatment;
  • Diagnosis occurred between 1 January 2000 and 31 December 2025;
  • Minimum follow-up of 12 months for patients without an event, unless recurrence or death occurred earlier;
  • Local review by a dedicated breast pathologist to confirm the diagnosis and the related molecular features, with particular attention to the confirmation of apocrine morphology.

Exclusion Criteria:

  • Pure IC NST without any lobular invasive component;
  • ER or PR expression >10% in the invasive component, in cases with negative HER2 status;
  • In situ lobular neoplasia (lobular carcinoma in situ) without an invasive component;
  • De novo stage IV disease (such patients, if they underwent surgery of the primary tumor, will be captured in a separate exploratory cohort for a dedicated analysis)
  • Synchronous invasive BC of another dominant histology requiring systemic treatment that precludes attribution of outcomes to HR-negative/low ILC;
  • Prior invasive BC under active systemic treatment at the time of diagnosis, unless clearly documented as unrelated and not expected to confound outcomes;
  • Insufficient data or follow up

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Triple-negative ILC
ER <1%, PR <1% and HER2-negative (IHC 0, 1+, or 2+ with negative ISH). Within this cohort, HER2 expression will be further categorized, where assessable, as HER2 null (IHC 0, no staining), HER2-ultralow (IHC 0+ with faint/incomplete staining in ≤10% of tumor cells) and HER2-low (IHC 1+, or 2+/ISH-negative).
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy
HER2-positive ILC
HER2-positive disease, defined as IHC 3+ or IHC 2+ ISH-positive. Subgroups within this cohort will include HR-negative ILC (ER and PR both <1%) and HR-positive (ER>10%) HER2-positive ILC.
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy
HR-low ILC (cross-cutting category)
ER and/or PR 1-10%, with neither receptor >10%, analyzed separately as a distinct group and also within the HER2-defined groups.
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy
Exploratory Subgroups (cross-cutting category)
Apocrine and/or LAR-featured ILC, and non-classic lobular variants (pleomorphic, histiocytoid and other rare histologic variants).
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Invasive disease-free survival (iDFS)
大体时间:Through study completion, an average of 5 years
Time from definitive surgery to first invasive event (ipsilateral invasive, locoregional invasive, or distant recurrence, contralateral invasive BC)
Through study completion, an average of 5 years

次要结果测量

结果测量
措施说明
大体时间
Overall survival (OS)
大体时间:Through study completion, an average of 5 years
Through study completion, an average of 5 years
Distant disease-free survival (DDFS)
大体时间:Through study completion, an average of 5 years
Through study completion, an average of 5 years
Breast cancer-specific survival (BCSS)
大体时间:Through study completion, an average of 5 years
Through study completion, an average of 5 years
Locoregional recurrence-free survival (LRRFS)
大体时间:Through study completion, an average of 5 years
Through study completion, an average of 5 years
Recurrence rate and patterns
大体时间:Through study completion, an average of 5 years
Local, regional, distant, contralateral, and site-specific distant (including ILC-enriched sites)
Through study completion, an average of 5 years

其他结果措施

结果测量
措施说明
大体时间
Pathologic complete response (pCR) - ypT0/Tis ypN0, with residual cancer burden (RCB) class distribution; in the neoadjuvant cohort, event-free survival (EFS) from treatment initiation where data permit
大体时间:Through study completion, an average of 5 years
Through study completion, an average of 5 years
Multidisciplinary treatment patterns and treatment-related outcomes according to therapeutic strategy (upfront surgery versus neoadjuvant treatment), surgical management (including reconstruction/oncoplastic approaches), systemic and radiation therapy
大体时间:Through study completion, an average of 5 years
Through study completion, an average of 5 years
Prognostic, predictive and potential therapeutic relevance of clinicopathologic, molecular, and biologic features
大体时间:Through study completion, an average of 5 years
Somatic and germline alterations, TME features (stromal TILs, PD-L1 status, immune-related biomarkers), apocrine differentiation, LAR phenotype, HER2 status, HR-negative versus HR-low status, and classic versus pleomorphic/non-classic ILC variants
Through study completion, an average of 5 years
Biomarker-outcome associations with iDFS, pCR and OS
大体时间:Through study completion, an average of 5 years
Through study completion, an average of 5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 学习椅:Francesco Milardi, MD、Veneto Institute of Oncology IRCCS

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月1日

初级完成 (估计的)

2027年5月1日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2026年5月19日

首先提交符合 QC 标准的

2026年5月23日

首次发布 (实际的)

2026年5月29日

研究记录更新

最后更新发布 (实际的)

2026年9月2日

上次提交的符合 QC 标准的更新

2026年8月30日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

其他研究编号

  • CESC IOV 2023-61

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.